- Home
- ITRG vs BCAB Comparison
ITRG vs BCAB Comparison
Compare ITRG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | BCAB |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.5M | 12.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ITRG | BCAB |
|---|---|---|
| Price | $2.51 | $0.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $5.13 | $1.00 |
| AVG Volume (30 Days) | ★ 2.7M | 1.3M |
| Earning Date | 03-24-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $733.38 | N/A |
| Revenue Next Year | $46.00 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.13 |
| 52 Week High | $4.87 | $1.43 |
Technical Indicators
Market Signals| Indicator | ITRG | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 28.06 | 40.31 |
| Support Level | $1.43 | $0.15 |
| Resistance Level | $3.24 | $0.21 |
| Average True Range (ATR) | 0.20 | 0.02 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 2.02 | 12.63 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.